Basecamp Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Basecamp Wealth Advisors's VRTX Position: Q3 2026 in Review
Basecamp Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q3 2026, selling an estimated $94.7K and leaving 641 shares worth $335K. The position accounts for 0.08% of the portfolio, ranked #133.
Basecamp Wealth Advisors first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $410K in Q2 2026. 1,772 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Basecamp Wealth Advisors held 641 shares of Vertex Pharmaceuticals worth $335K as of Q3 2026.
- Basecamp Wealth Advisors sold 185 Vertex Pharmaceuticals shares in Q3 2026, an estimated $94.7K.
- Vertex Pharmaceuticals made up 0.08% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #133 holding.
- Basecamp Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
- Basecamp Wealth Advisors's Vertex Pharmaceuticals position peaked at $410K in Q2 2026.
- 1,772 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.